OncoMatch/Clinical Trials/NCT06341894
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Is NCT06341894 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Dalpiciclib and Endocrine therapy for early breast cancer.
Treatment: Dalpiciclib · Endocrine therapy — The investigator conduct a phase II multi-center, open-label trial to evaluate efficacy and safety of dalpiciclib with endocrine therapy as adjuvant treatment in patients with medium /high risk hormone receptor-positive, HER2-negative Early Breast Cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER ≥10%)
immunohistochemical ER and/or PR≥10%
Required: PR (PGR) overexpression (PR ≥10%)
immunohistochemical ER and/or PR≥10%
Required: HER2 (ERBB2) wild-type
HER2-
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC
Excluded: Stage IV
anatomic stages of IIA-IIIC stage (T2-4N0-3M0), of which stage IIA only included T1N1M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06341894 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ESR1?
Yes, ESR1 overexpression is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIA or IIB or IIIA or IIIB or IIIC is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify